Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 248 of the 249 references it cites were found in a registry or an index.
Abstract
In vivo exploration of activated microglia in neurodegenerative diseases is achievable by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders. The extent and upregulation of TSPO as a molecular biomarker of activated microglia in the human brain is now widely documented in these pathologies, but its significance, and especially its protective or deleterious action regarding the disease’s stage, remains under debate. Thus, we exposed new and plausible suggestions to enhance the contribution of TSPO PET imaging for biomedical research by exploring microglia’s role and interactions with other cells in brain parenchyma. Multiplex approaches, associating TSPO PET radiopharmaceuticals with other biomarkers (PET imaging of cellular metabolism, neurotransmission or abnormal protein aggregates, but also other imaging modalities, and peripheral cytokine levels measurement and/or metabolomics analysis) was considered. Finally, the actual clinical impact of TSPO PET imaging as a routine biomarker of neuroinflammation was put into perspective regarding the current development of diagnostic and therapeutic strategies for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The translocator protein, a hallmark of activated microglia, serves as the gold standard for PET-based neuroinflammation imaging [57].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Methods to image microglia exist and are being used to test the effect of treatments on microglia205–210.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“MCI represents a diagnostic entity for the transition between normal aging and AD dementia [113].”
BackgroundPolazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“HD is neuropathologically characterized by the formation of intranuclear inclusions of mHTT [81] resulting in striatal, cortical and hypothalamic atrophy [82,83] which are associated with an accumulation of reactive microglia in these same regions [31,84].”
BackgroundResting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 1×
“Several cellular actors including neurons, astrocytes, T-cells and the blood brain barrier (BBB) modulate microglial function and form a very dynamic network [5].”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“, amoeboid, rod, multi-nucleated, epithelioid or dystrophic state) and functional changes of microglia, known as microglial “activation” [6,9].”
Background
Cited by
Items 101–185 of 185
Neuroinflammation in dementia: A meta-analysis of PET imaging studies
Pan, J., Hu, J., Meng, D., Chen, L., & Wei, X. (2024) · Medicine · doi:10.1097/md.0000000000038086 · Cited by 13
“[9,10] Thus, PET imaging provides us with a powerful means of assessing neuroinflammation and exploring its relationship with cognitive decline.”
BackgroundPerani, D., Iaccarino, L., Jacobs, A. H., IMBI Brain Imaging Working Group, Lammertsma, A. A., Nordberg, A. K., Windhorst, A. D., Gerhard, A., Winkeler, A., Jacobs, A. H., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.004 · Cited by 13
“[22] Dupont A-C, Largeau B, Santiago RibeiroMJ, Guilloteau D, Tronel C, Arlicot N.”
BackgroundMethodSelf-citationBasic Science of PET Imaging for Inflammatory Diseases
Kubota, K., Ogawa, M., Ji, B., Watabe, T., Zhang, M., Suzuki, H., Sawada, M., Nishi, K., & Kudo, T. (2019) · Springer eBooks · doi:10.1007/978-981-15-0810-3_1 · Cited by 15
Activated microglia by 18F-DPA714 PET in a case of anti-LGI1 autoimmune encephalitis
Wang, J., Jin, L., Zhang, X., Yu, H., Ge, J., Deng, B., Li, M., Zuo, C., & Chen, X. (2022) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2022.577879 · Cited by 11
Potential Alzheimer’s disease drug targets identified through microglial biology research
Lepiarz‐Raba, I., Hidayat, T., Hannan, A. J., & Jawaid, A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2335210 · Cited by 10
“Amyloid positron emission tomography (PET) scans are now routinely used as a diagnostic aid in the clinic, whereas translocator protein (TSPO) PET imaging has emerged as a reliable real-time indicator of microglial activation in the brain [154].”
Neurodegeneration and the immune system: lessons from autoimmune encephalitis
Campetella, L., Smolik, K., Farina, A., Joubert, B., Muñiz‐Castrillo, S., Desestret, V., & Honnorat, J. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13094-0 · Cited by 13
“With a similar approach, microglial activation has been demonstrated in vivo in other neurodegenerative disorders [151], such as Parkinson’s disease [152], MSA [153], Lewy body dementia [154] and ALS [155].”
Faecal microbiota transplant for Parkinson’s disease: promises and future directions
Tan, E. K., Wang, J. D. J., Pettersson, S., Wang, Q., Takahashi, R., Poewe, W. H., Jankovic, J. J., & Rascol, O. (2025) · Brain · doi:10.1093/brain/awaf419 · Cited by 12
Mou, T., Tian, J., Tian, Y., Yun, M., Li, J., Dong, W., Lu, X., Zhu, Z., Mi, H., Zhang, X., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75705-2 · Cited by 9
Shimochi, S., Keller, T., Kujala, E., Khabbal, J., Rajander, J., Löyttyniemi, E., Solin, O. H., Nuutila, P., Kanaya, S., Yatkin, E., et al. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01713-5 · Cited by 10
“In vivo positron emission tomography (PET) imaging of neuroinflammation attributed to TSPO expression is an attractive method for evaluating disease progression and therapeutic outcomes [8, 9].”
Graf, R., Longo, J. L., & Hughes, Z. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118779383 · Cited by 13
“The endotoxin, lipopolysaccharide (LPS), is used to induce inflammation and has been shown to cause apathy, anxiety and decreased alertness in humans (Dupont et al., 2017; Grigoleit et al., 2011).”
BackgroundMaccioni, L., Brusaferri, L., Barzon, L., Schubert, J. J., Nettis, M. A., Cousins, O., Rosenzweig, I., Mizuno, Y., Vicente‐Rodríguez, M., Singh, N., et al. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251361261 · Cited by 8
Joo, Y., Lee, M.-W., Son, Y., Chang, K., Yaqub, M. M., Kim, H.-K., Cumming, P. D., & Kim, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010034 · Cited by 13
“Positron emission tomography (PET) imaging with ligands for the 18-kDa translocator protein (TSPO) enables the assessment in the living human brain of microglial activation, which is an index of the state of neuroinflammation in vivo [6,7].”
BackgroundFujinaga, M., Kumata, K., Zhang, Y., Hatori, A., Yamasaki, T., Mori, W., Ohkubo, T., Xie, L., Nengaki, N., & Zhang, M. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01700j · Cited by 9
Schoenberg, P. L. A., Song, A. K., Mohr, E., Rogers, B. P., Peterson, T. E., & Murphy, B. A. (2023) · Human Brain Mapping · doi:10.1002/hbm.26491 · Cited by 9
“Overexpression of TSPO in microglia is also acutely abundant in the core infarction of focal cerebral ischemia and following traumatic brain injury/stroke (Dupont et al., 2017; Hernandez-Ontiveros et al., 2013; Jiang et al., 2020; Li et al., 2021).”
BackgroundWeng, C.-C., Carlin, S., Hou, C., Metz, T., Li, S., Lee, H. S., Xu, K., Makvandi, M., & Mach, R. H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.062 · Cited by 8
Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET
Donat, C. K., Mirzaei, N., Tang, S.-P., Edison, P., & Sastre, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_22 · Cited by 8
Current Developments on [18F]FDG PET/CT in Inflammatory Disorders of the Central Nervous System
Stormezand, G. N., Doorduin, J., Glaudemans, A. W. J. M., van der Hoorn, A., & de Jong, B. M. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.06.001 · Cited by 10
Sossi, V. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.034 · Cited by 7
Giordani, A., Menziani, M. C., Moresco, R. M., Matarrese, M., Paolino, M., Saletti, M., Giuliani, G., Anzini, M., & Cappelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00379 · Cited by 6
Kang, S., Kim, J., Lee, S., Okamura, N., & Chang, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105485 · Cited by 6
“TSPO is considered a promising biomarker for neurodegenerative diseases because of the correlation between TSPO overexpression and microglial activation [10].”
BackgroundCantero‐Fortiz, Y., Butler, C., Montalbán, X., & Boada, M. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1805691 · Cited by 9
“…senescence-like activity in vivo ; and multi-omics frameworks delineate senescence-linked networks and molecular biotypes that map onto clinical phenotypes and risk trajectories (Barro et al., 2020; Dhauria et al., 2024; Guo et al., 2024; Werry et al., 2019; Pan et al., 2024; Dupont et al., 2017).”
Wongso, H., Kurniawan, A., Setiadi, Y., Kusumaningrum, C. E., Widyasari, E. M., Wibawa, T. H. A., Mahendra, I. N. B., Febrian, M. B., Sriyani, M. E., Halimah, I., et al. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.015 · Cited by 9
“45 Emerging evidence also indicated that the existence of TSPO had been found in a diverse number of cancerous cells in humans, such as brain, oral, prostate, oesophageal cancers, colon, breast, and ovarian cancers, as well as endometrial and hepatic carcinomas.”
BackgroundZare, M.-S., Abedpoor, N., Hajibabaie, F., & Walker, A. K. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106944 · Cited by 6
“…and translocator protein neuroimaging of reactive microglia and astrocytes have been associated with cognitive symptoms in patients with neurodegenerative disorders and cancer patients receiving chemotherapy (Dupont et al., 2017; Pomykala et al., 2013; Schroyen et al., 2021; Yin et al., 2023).”
Imaging in Neurodegeneration: Movement Disorders
Sossi, V., Cheng, J.-C. K., & Klyuzhin, I. S. (2018) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2018.2871760 · Cited by 6
“Several other tracers have been developed with better binding properties, the so-called second and third generation TSPO tracers; results from many studies however remain controversial [40].”
BackgroundCharacteristics of TSPO expression in marmoset EAE
Falk, I., Maric, D., Leibovitch, E., Sati, P., Lefeuvre, J., Luciano, N. J., Guy, J., Ha, S.-K., Owen, D. R., Aigbirhio, F., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03343-4 · Cited by 5
Kalina, T., Berroterán-Infante, N., Schmitl, S., Vraka, C., Hacker, M., Mitterhauser, M., Pallitsch, K., & Wadsak, W. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0444 · Cited by 5
Jafarinia, M., Lotfi, N., Rezaei, N., Rastgoo, E., Shahraki, B. K., & Zahedi, G. (2023) · Galen Medical Journal · doi:10.31661/gmj.v12i.3109 · Cited by 8
“The PET tracer binds to the mitochondrial translocator protein (TSPO) and leads to increases in activated microglia and pro-inflammatory astro - cytes [107].”
BackgroundBooth, S., & Ko, J. H. (2024) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-024-00842-9 · Cited by 5
Positron Emission Tomography (PET) Imaging Biomarkers in Huntington’s Disease
Everix, L., Staelens, S. G., & Bertoglio, D. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_6 · Cited by 4
Raman, F., Grandhi, S., Murchison, C., Kennedy, R., Landau, S. M., Roberson, E. D., McConathy, J., & Initiative, A. D. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190329 · Cited by 4
“…can accommodate any DICOM dataset, other neuroimaging modalities, such as ioflupane-SPECTforParkinson’sdiseaseorfunctionalMRIand diffusion tensor imaging for schizophrenia, could be processed along with PET neuroimaging biomarkers of neuroinflammation [50–52] by adapting the BLAzER methodology.”
Родина, А. В., Semochkina, Y. P., Vysotskaya, O. V., Parfenova, A., & Moskaleva, E. Y. (2023) · International Journal of Radiation Biology · doi:10.1080/09553002.2023.2177765 · Cited by 6
Zhou, J., Yang, C., Xv, Q., Wang, L., Shen, L., & Lv, Q.-W. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s438503 · Cited by 4
“11– 13,17–19 –13,17–19 Accumulating evidence has shown that TSPO participates in a diverse spectrum of microglial inflammatory responses, including cytokine secretion, proliferation, motility, and phagocytosis.”
BackgroundMitochondrial Dysfunction in Neurodegenerative Diseases
Chen, C., Zhao, Y., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Yang, X., Lu, M., et al. (2025) · MedComm · doi:10.1002/mco2.70326 · Cited by 4
“The 18 F-DPA-714 PET probe targeting the mitochondrial 18 kDa translocator protein (TSPO) is utilized for the study of neuroinflammation in NDDs [116, 117].”
Matsudaira, T., Terada, T., Obi, T., Yokokura, M., Takahashi, Y., & Ouchi, Y. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00617-1 · Cited by 3
“PET imaging of TSPO is widely used to monitor neuroinflammation in neurological and psychiatric disorders [9, 12].”
BackgroundMethodPissarek, M. (2018) · World Journal of Neuroscience · doi:10.4236/wjns.2018.81006 · Cited by 3
“The broader clinical experience with second generation compounds suggests that the tracers among these with the best properties, like [(18)F]FEPPA or [(11)C]PBR28 and its fluorinated analogue remain on the schedule of clinical trials [138] [139] [140].”
BackgroundAssessment of 18F-PBR-111 in the Cuprizone Mouse Model of Multiple Sclerosis
Jewells, V. L., Yuan, H., Merrill, J. R., Frank, J. E., Patel, A., Cohen, S. M., Giglio, B. C., Feinberg, N. N., Matsushima, G. K., & Li, Z. (2021) · Diagnostics · doi:10.3390/diagnostics11050786 · Cited by 4
“TSPO agent utility, however, extends beyond MS because similar pathophysiologic changes are also seen in ALS, Psychiatric disorders, Alzheimer’s, Parkinson’s, and Huntington’s disease, as well as colitis [26,27].”
BackgroundAnzilotti, S., Iesu, N. D., Gargiulo, S., Muraglia, N. D., Cicatiello, A. G., Dentice, M., Panico, M., Albanese, S., Annunziato, L., Salvatore, M., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202502450r · Cited by 3
Wang, Y., Wang, Y., Zhang, W., Xu, Y., Narayan, N. S., Cheng, H., Yang, H., Huang, Y., Zhang, C. M., & Wang, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02549 · Cited by 2
Synaptic correlates of benzodiazepine tolerance
Piot, A., & Jovanovic, J. N. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03512-8 · Cited by 5
“In the brain, it is one of the well-established neuroin fl ammatory markers utilized in diagnostic imaging [73] because its expression is triggered by neuroin fl ammation [74] and brain injury [75].”
Translocator protein 18 kDa: a potential therapeutic biomarker for post traumatic stress disorder
Qiu, Z.-K., Liu, X., Chen, Y., Wu, R.-J., Guan, S.-F., Pan, Y., Wang, Q., Tang, D., Zhu, T., & Chen, J. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00548-9 · Cited by 2
“Moreover, the protein is one of the commonly used markers of inflammation in positron emission tomography (PET) (Lavisse et al. 2012; Richards et al. 2018).”
BackgroundAertker, B. M., Kumar, A., Cardenas, F., Gudenkauf, F. J., Sequeira, D. J., Prossin, A. R., Srivastava, A. K., Cox, C. S., & Bedi, S. S. (2021) · ASN NEURO · doi:10.1177/17590914211014135 · Cited by 3
Aceves-Serrano, L., Neva, J. L., Munro, J., Vavasour, I. M., Parent, M., Boyd, L. A., & Doudet, D. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301118 · Cited by 3
“…of glial activation in vivo can be carried using tools such as positron emission tomography (PET), which has proven to be a valuable tool for assessing neuroinflammatory processes by targeting the translocator protein (TSPO) [18,19], a molecule that is over-expressed in activated microglia [20].”
BackgroundVora, N., Patel, P. K., Marsool, M. D. M., Marsool, A. D. M., Sunasra, R., Ladani, P., Pati, S., Khoont, D., Prajjwal, P., & Ranjan, R. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.101863 · Cited by 4
Expression and purification of the mammalian translocator protein for structural studies
Graeber, E., & Korkhov, V. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198832 · Cited by 2
Tang, C., & Militano, V. (2019) · Springer eBooks · doi:10.1007/978-3-030-01523-7_3 · Cited by 2
Lum, J. S., du Bois, T. M., Mattner, F., Katsifis, A. G., Brown, S. J., Huang, X., & Newell, K. A. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.041 · Cited by 2
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083560 · Cited by 1
“The translocator protein, a hallmark of activated microglia, serves as the gold standard for PET-based neuroinflammation imaging [57].”
The Mitochondrial 18 kDa Translocator Protein as a Biomarker of Radiation-Induced Neuroinflammatory
Родина, А. В. (2024) · Medical Radiology and radiation safety · doi:10.33266/1024-6177-2024-69-3-35-45 · Cited by 2
Katiyar, D., & Manish, M. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100126 · Cited by 2
Updates of nuclear medicine imaging in neurodegenerative disorders
Huang, S., Lin, K., Hung, G., & Hsiao, I. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.11.032 · Cited by 2
Maiti, S., Yadav, S. K., Teitz, M., Velarde, E., Lee, S., Lecksell, K., Bibic, A., & Ngen, E. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-37264-w · Cited by 2
Jaiswal, S., Smith, A. N., Gregor, A., Purnomo, S., Basuli, F., Shi, J., Swenson, R. E., Hood, M. N., Ho, V. B., & Byrnes, K. R. (2026) · Journal of Neurotrauma · doi:10.1177/08977151261433934 · Cited by 1
Morton, L., Villafuerte, L. E., Garza, A. P., Lindemann, N., Wider-Eberspächer, E., Bruder, D., & Dunay, I. R. (2026) · Glia · doi:10.1002/glia.70208 · Cited by 1
“…neu-roimmune biomarkers (e.g., serum neurofilament light chain [Gaetani et al. 2019; Gisslén et al. 2016; Kuhle et al. 2016]), CSF cytokines, and PET imaging of microglial activation using TSPO ligands (Dupont et al. 2017; Airas et al. 2015) to capture central nervous system disease activity.”
An Improved HPLC Separation Method for TSPO Radioligand [11C]ER176 Clinical Production
Li, K., & Cai, H. (2024) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4093 · Cited by 1
Biomarkers used in Alzheimer's disease diagnosis
Mishra, S. K., Singh, R., Chang, H., Obaid, A. A., & Singh, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00013-6 · Cited by 1
Astroglial Pathology in Major Depressive Disorders: Metabolic and Molecular Aspects
Sarawagi, A., Bhat, U. A., Sinha, S., Iyer, H., Patel, A. B., & Kumar, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-8313-8_11 · Cited by 1
Pantaleão, L. D. N. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2017.tde-07122017-160130
Bezukladova, S. (2018) · Doria (University of Helsinki)
Applications of Neuroimaging Biomarkers in CNS Drug Development
Cole, P. E., & Einstein, S. G. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00009-6 · Cited by 2
Comorbid Metabolic Syndrome and Prodromal Alzheimer's Disease in a Rat Model
Ivanova, N. A. (2019) · Scholarship@Western (Western University)
Lee, S. J., Ko, N. R., & Oh, S. J. (2020) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12071
Influences On Monoamine Oxidase Activity In The Brain And Translation Into Major Depressive Disorder
Raitsin, S. (2018) · TSpace (University of Toronto)
Molecular imaging findings in bipolar disorder
Meyer, J. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819182-8.00016-8 · Cited by 1
Huang, C., Ding, F., Hu, Z., Wang, M., Peng, W., Li, W. S., Wang, C., & Tang, D. (2020) · doi:10.21203/rs.3.rs-39569/v1
“Of these radiotracers, the most common one used to date is 11C-PK11195[6], which nonetheless has several limitations, including high non-speci c binding, low brain penetrance, low signalto-noise ratio (SNR), low sensitivity, as well as poor amenability to quanti cation[9].”
BackgroundTracking Neurodegeneration: Advancement in Experimental Study Models
Arumugam, M., & Sugin Lal Jabaris, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-6703-9_3
Huang, C., Ding, F., Hao, Y., Hu, Z., Wang, C., Li, W., Wang, M., Peng, W., & Tang, D. (2020) · doi:10.21203/rs.3.rs-39569/v2
Research Progress of Biomarkers for the Di-agnosis of Alzheimer’s Disease
张, 悦. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281136
Simultaneous PET and MR Imaging of the Human Brain
Catana, C., Sander, C. Y. M., Sorensen, A. G., & Rosen, B. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_49
Liu, Y., & White, M. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_46
Parkinson’s Disease and Lewy Body Dementias
Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_23
Yang, A., Peng, B., Teng, F., Chen, Y., Zhang, S., Yang, F., Xia, Y., & Geng, B. (2026) · Life Sciences in Space Research · doi:10.1016/j.lssr.2026.03.005
Along-tract and across-plexus propagation of tissue damage in multiple sclerosis
Ricigliano, V. A. G. (2021) · theses.fr (ABES) · doi:10.70675/d9e05903zbf45z4f3cz9290z50f80f3e4ead
Biomimetic MRI Nanoprobe for Mapping Cerebrovascular Inflammation After Traumatic Brain InjuryPreprint
Rousseau, J., Simmons, A., Kim, M., Ortega, D., Alzubi, O. M., Wang, T.-Y., Bartelle, B. B., Stabenfeldt, S. E., & Wang, K.-C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727244
“Molecular imaging strategies such as translocator protein positron emission tomography (TSPO-PET) have been investigated to address this limitation ( 13 ).”
Microglial activation and neuroinflammation: implications for neuropsychiatric symptoms
Uddin, T., Halder, C., Asma, A., Zaheen, A., Nahian, A., Nipun, R. S., Ferdous, J., Sarker, R., Misha, M. M., Tasnim, S., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004158
Song, H., Zhu, Z., Xiao, L., Zhao, Q., Li, C., Lv, A., Yu, X., Gao, Z., Lin, J., Wang, Y., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03829-9
Neuroinflammation and Tauopathies
Zeenny, M.-N., Salame, I., Maatouk, L., & Akoury, E. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12253-4
“Elevated CSF cytokines may serve as indica - tors of active neuroimmune signaling, whereas longitudinal TSPO PET changes correlate with disease progression and regional atrophy [ 131].”
Yang, L., Wang, L., Guo, J., Zhang, H., Xu, H., He, M., Wan, G., Xia, L., Zhou, Q., & Wang, Y. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108418
Blood-Based Biomarkers for Post-Stroke Cognitive Impairment
Pu, J., Guo, W., Li, H., Wang, Z., Mu, T., Xie, F., Chen, J., Cao, J., Zhong, C., Li, H., et al. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070702
“TSPO expression is regarded as an indicator of brain damage and neuroinflammatory activity in various neurological conditions, such as encephalitis, stroke, and head trauma [78].”
Xia, Y., Lu, J., & Feng, X. (2026) · Dentistry Journal · doi:10.3390/dj14080495
“Similarly, TSPO-PET has been used to investigate neuroinflammation in several neurological conditions [137], but direct clinical validation in TMD remains lacking [148,149].”
Cheng, H., Narayan, N. S., Wang, Y., Wang, Y., Huang, Y., Yang, H., Tokala, R., Yan, J., Downey, J. W., Siewko, A., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103682
“Compared with TSPO imaging, which can be affected by genetic polymorphisms (e.g., rs6971), IDO1-targeted imaging may provide complementary information related to metabolic and enzymatic changes within the KP [45].”
Zhang, F., Sun, Z.-H., Zheng, Q., Wang, Z.-X., Tao, X.-L., Huo, B.-Q., Yu, J., & Wang, S.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19101553
BindingDB (2023) · UC San Diego · doi:10.7270/q25d8wsd
Metadata
- Authors
- Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N.
- Affiliations
- Inserm (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France
- Corresponding author
- Dupont, Anne-Claire
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-04-07
- Volume
- 18
- Issue
- 4
- Pages
- 785
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5412369
- OpenAlex
- W2605220880
- Cited by
- 182
- References
- 249
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 10 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 34 · 2019: 31 · 2018: 25 · 2017: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Agence Nationale de la Recherche (ANR-11-LABX-0018)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- translocator protein (TSPO), TSPO PET imaging, microglial activation, neuroinflammation, neurodegenerative diseases, Parkinson's disease, Huntington's disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, mental illness, molecular biomarkers, radiopharmaceuticals, multiplexed imaging, cytokines, metabolomics
- MeSH terms
- Humans, Biomarkers, Up-Regulation, Microglia, Receptors, GABA, Radiopharmaceuticals, Neurodegenerative Diseases, Early Diagnosis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.